NUVB – nuvation bio inc. class a (US:NASDAQ)

News

Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com